104 related articles for article (PubMed ID: 11592575)
1. Gliclazide-induced hepatitis, hemiplegia and dysphasia in a suicide attempt.
Caksen H; Kendirci M; Tutuş A; Uzüm K; Kurtoğlu S
J Pediatr Endocrinol Metab; 2001; 14(8):1157-9. PubMed ID: 11592575
[TBL] [Abstract][Full Text] [Related]
2. Acute renal failure after massive ingestion of gliclazide in a suicide attempt.
Barracca A; Ledda O; Michittu B; Pili GF; Manca O; Pani A; Altieri P
Ren Fail; 1998 May; 20(3):533-7. PubMed ID: 9606741
[TBL] [Abstract][Full Text] [Related]
3. Dilemma of diagnosing sulphonylurea overdose in children: deliberations and considerations before reaching a diagnosis.
Gopal-Kothandapani JS; Wright KP; Sithambaram S; Natarajan A
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28847991
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic pitfalls in sulfonylurea-induced neuroglycopenic syndrome with hemiparesis, dysphasia and somnolence].
Holstein A; Lankes HG; Egberts EH
Med Klin (Munich); 1998 Jun; 93(6):374-7. PubMed ID: 9662945
[TBL] [Abstract][Full Text] [Related]
5. Gliclazide-induced acute hepatitis.
Dourakis SP; Tzemanakis E; Sinani C; Kafiri G; Hadziyannis SJ
Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):119-21. PubMed ID: 10656221
[TBL] [Abstract][Full Text] [Related]
6. Severe neuroglycopaenia secondary to severe hypoglycaemia from serendipitous overdose of gliclazide without adrenergic or autonomic response.
Ling GR; Singh K; Wong SY; Toh VK
Diabet Med; 2009 Nov; 26(11):1182-3. PubMed ID: 19930002
[No Abstract] [Full Text] [Related]
7. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.
Portha B; Serradas P
Am J Med; 1991 Jun; 90(6A):15S-21S. PubMed ID: 1831320
[TBL] [Abstract][Full Text] [Related]
8. Suppression by 2-ketoisocaproate of the insulinotropic action of hypoglycemic sulfonylureas.
Malaisse WJ; Mathias PC; Malaisse-Lagae F; Sener A
Res Commun Chem Pathol Pharmacol; 1985 Feb; 47(2):265-84. PubMed ID: 3922019
[TBL] [Abstract][Full Text] [Related]
9. Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats.
Dachicourt N; Bailbé D; Gangnerau MN; Serradas P; Ravel D; Portha B
Eur J Pharmacol; 1998 Nov; 361(2-3):243-51. PubMed ID: 9865514
[TBL] [Abstract][Full Text] [Related]
10. Is gliclazide a sulfonylurea with difference? A review in 2016.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle.
Rodríguez E; Pulido N; Romero R; Arrieta F; Panadero A; Rovira A
Endocrinology; 2004 Feb; 145(2):679-85. PubMed ID: 14563700
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose.
Gul M; Cander B; Girisgin S; Ayan M; Kocak S; Unlu A
Adv Ther; 2006; 23(6):878-84. PubMed ID: 17276956
[TBL] [Abstract][Full Text] [Related]
13. Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
Serradas P; Bailbé D; Portha B
Diabetologia; 1989 Aug; 32(8):577-84. PubMed ID: 2528491
[TBL] [Abstract][Full Text] [Related]
14. Multi-modal brain imaging showing brain damage to the orbitofrontal cortex and left hemisphere, in a case of prolonged hypoglycemia-induced transient hemiplegia followed by persistent encephalopathy.
Koike S; Sasaki R
Psychiatry Clin Neurosci; 2013 Jul; 67(5):360-2. PubMed ID: 23711198
[TBL] [Abstract][Full Text] [Related]
15. Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
Harrower A
Metabolism; 2000 Oct; 49(10 Suppl 2):7-11. PubMed ID: 11078469
[TBL] [Abstract][Full Text] [Related]
16. The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Karunakaran S; Hammersley MS; Morris RJ; Turner RC; Holman RR
Metabolism; 1997 Dec; 46(12 Suppl 1):56-60. PubMed ID: 9439561
[TBL] [Abstract][Full Text] [Related]
17. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
Colagiuri S; Matthews D; Leiter LA; Chan SP; Sesti G; Marre M
Diabetes Res Clin Pract; 2018 Sep; 143():1-14. PubMed ID: 29802958
[TBL] [Abstract][Full Text] [Related]
18. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
Chazan AC; Gomes MB
Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].
Procacci V; Giovine A; Roberto MG; Di Reda N; Lasorsa G; Vendemiale G; Stufano N; Altomare E
Boll Soc Ital Biol Sper; 1988 Sep; 64(9):817-24. PubMed ID: 3072977
[No Abstract] [Full Text] [Related]
20. Gliclazide.
Al-Omary FAM
Profiles Drug Subst Excip Relat Methodol; 2017; 42():125-192. PubMed ID: 28431776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
